64Cu-DOTA-Rituximab PET/CT of B-Cell Non-Hodgkin Lymphoma for Imaging the CD20 Expression.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000004378
Abstract: ABSTRACT 64Cu-DOTA-rituximab PET/CT was performed on a 62-year-old and a 71-year-old men diagnosed with B-cell non-Hodgkin lymphoma. Compared with 18F-FDG PET/CT, lesions could be detected more sensitively, and it was confirmed that there was no… read more here.
Keywords: 64cu dota; dota rituximab; rituximab pet;